BRPI0817275A2 - Combinação farmacêutica de alisquireno e valsartana - Google Patents
Combinação farmacêutica de alisquireno e valsartanaInfo
- Publication number
- BRPI0817275A2 BRPI0817275A2 BRPI0817275-7A BRPI0817275A BRPI0817275A2 BR PI0817275 A2 BRPI0817275 A2 BR PI0817275A2 BR PI0817275 A BRPI0817275 A BR PI0817275A BR PI0817275 A2 BRPI0817275 A2 BR PI0817275A2
- Authority
- BR
- Brazil
- Prior art keywords
- aliskiren
- valsartan
- minutes
- dose combination
- fixed dose
- Prior art date
Links
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 title abstract 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 3
- 229960004601 aliskiren Drugs 0.000 title abstract 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 3
- 229960004699 valsartan Drugs 0.000 title abstract 3
- 229940000425 combination drug Drugs 0.000 abstract 3
- 238000004090 dissolution Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97590507P | 2007-09-28 | 2007-09-28 | |
| PCT/US2008/077417 WO2009045796A1 (en) | 2007-09-28 | 2008-09-24 | Pharmaceutical combination of aliskiren and valsartan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0817275A2 true BRPI0817275A2 (pt) | 2015-06-16 |
Family
ID=40394241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0817275-7A BRPI0817275A2 (pt) | 2007-09-28 | 2008-09-24 | Combinação farmacêutica de alisquireno e valsartana |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100247645A1 (pt) |
| EP (1) | EP2205279B1 (pt) |
| JP (1) | JP2010540548A (pt) |
| KR (1) | KR20100059912A (pt) |
| CN (1) | CN101808665A (pt) |
| AT (1) | ATE505203T1 (pt) |
| AU (1) | AU2008309059A1 (pt) |
| BR (1) | BRPI0817275A2 (pt) |
| CA (1) | CA2697437A1 (pt) |
| DE (1) | DE602008006243D1 (pt) |
| ES (1) | ES2364538T3 (pt) |
| MX (1) | MX2010003439A (pt) |
| PL (1) | PL2205279T3 (pt) |
| PT (1) | PT2205279E (pt) |
| RU (1) | RU2010116526A (pt) |
| WO (1) | WO2009045796A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2535090C2 (ru) * | 2009-01-28 | 2014-12-10 | Новартис Аг | Галеновы препараты органических соединений |
| MX2011009846A (es) * | 2009-03-20 | 2011-09-29 | Novartis Ag | Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno. |
| WO2011116115A1 (en) * | 2010-03-16 | 2011-09-22 | Novartis Ag | Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing |
| SG174658A1 (en) * | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| AU2012253667B2 (en) | 2011-05-10 | 2017-06-01 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
| CN102247344A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血压组合物 |
| CN102626395B (zh) * | 2012-04-19 | 2014-02-26 | 海南美兰史克制药有限公司 | 一种阿利克仑缬沙坦药物组合物脂质体固体制剂 |
| WO2013166114A1 (en) * | 2012-05-01 | 2013-11-07 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe |
| WO2013166117A1 (en) * | 2012-05-01 | 2013-11-07 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
| US10376470B2 (en) * | 2012-05-01 | 2019-08-13 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
| RU2718906C2 (ru) | 2016-01-20 | 2020-04-15 | Теравида, Инк. | Способы и композиции для лечения гипергидроза |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| MX2007004020A (es) * | 2004-10-08 | 2007-05-24 | Novartis Ag | Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica. |
| WO2006102177A2 (en) * | 2005-03-22 | 2006-09-28 | Novartis Ag | Biomarkers for efficacy of aliskiren as a hypertensive agent |
| BRPI0612674B8 (pt) * | 2005-06-27 | 2021-05-25 | Daiichi Sankyo Co Ltd | preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio |
-
2008
- 2008-09-24 BR BRPI0817275-7A patent/BRPI0817275A2/pt not_active IP Right Cessation
- 2008-09-24 MX MX2010003439A patent/MX2010003439A/es active IP Right Grant
- 2008-09-24 WO PCT/US2008/077417 patent/WO2009045796A1/en not_active Ceased
- 2008-09-24 AT AT08835893T patent/ATE505203T1/de active
- 2008-09-24 ES ES08835893T patent/ES2364538T3/es active Active
- 2008-09-24 EP EP08835893A patent/EP2205279B1/en not_active Not-in-force
- 2008-09-24 KR KR1020107006602A patent/KR20100059912A/ko not_active Withdrawn
- 2008-09-24 PT PT08835893T patent/PT2205279E/pt unknown
- 2008-09-24 JP JP2010527092A patent/JP2010540548A/ja active Pending
- 2008-09-24 CA CA2697437A patent/CA2697437A1/en not_active Abandoned
- 2008-09-24 DE DE602008006243T patent/DE602008006243D1/de active Active
- 2008-09-24 RU RU2010116526/15A patent/RU2010116526A/ru not_active Application Discontinuation
- 2008-09-24 CN CN200880108475A patent/CN101808665A/zh active Pending
- 2008-09-24 PL PL08835893T patent/PL2205279T3/pl unknown
- 2008-09-24 US US12/679,052 patent/US20100247645A1/en not_active Abandoned
- 2008-09-24 AU AU2008309059A patent/AU2008309059A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101808665A (zh) | 2010-08-18 |
| US20100247645A1 (en) | 2010-09-30 |
| EP2205279B1 (en) | 2011-04-13 |
| EP2205279A1 (en) | 2010-07-14 |
| ATE505203T1 (de) | 2011-04-15 |
| MX2010003439A (es) | 2010-04-21 |
| RU2010116526A (ru) | 2011-11-10 |
| ES2364538T3 (es) | 2011-09-06 |
| KR20100059912A (ko) | 2010-06-04 |
| DE602008006243D1 (de) | 2011-05-26 |
| CA2697437A1 (en) | 2009-04-09 |
| JP2010540548A (ja) | 2010-12-24 |
| PL2205279T3 (pl) | 2011-09-30 |
| WO2009045796A1 (en) | 2009-04-09 |
| AU2008309059A1 (en) | 2009-04-09 |
| PT2205279E (pt) | 2011-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0817275A2 (pt) | Combinação farmacêutica de alisquireno e valsartana | |
| TN2010000135A1 (en) | Galenical formulations of organic compounds | |
| MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
| CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
| ATE540680T1 (de) | Pharmazeutische aripiprazol-zusammensetzungen | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| AR061446A1 (es) | Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico | |
| IL193252A0 (en) | N-hydroxyacrylamide compounds | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| NZ628513A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
| WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
| MX2010002735A (es) | Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno. | |
| TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| JO3239B1 (ar) | تركيبات جالينية من مركبات عضوية | |
| MX2009005804A (es) | Composicion farmaceutica de memantina. | |
| MXPA05007253A (es) | Sales novedosas de derivados anticonvulsivantes. | |
| AR067351A1 (es) | Combinacion de picotamida con nafronil | |
| TN2011000100A1 (en) | Galenical formulations of organic compounds | |
| MX2011009846A (es) | Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno. | |
| TW200833375A (en) | Pharmaceutical compositions | |
| CY1110563T1 (el) | Παραγωγο του ισοξαζολικου οξεος για την ανακουφιση νευροπαθητικου πονου | |
| MY154883A (en) | A combination composition | |
| UA87224C2 (ru) | Применение 24-нор-урсодеоксихолевой кислоты для лечения холестатических заболеваний печени | |
| WO2008120131A3 (en) | Pharmaceutical compositions of diclofenac and misoprostol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |